# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:EW) with a Overweight and lowers the price target from $90...
Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:EW) with a Overweight and lowers the price target f...
- SEC Filing
Edwards Lifesciences (NYSE:EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively ...